慢性肾脏病患者活性维生素D3与颈动脉粥样硬化的相关性研究
2017-07-25赖玉萍张舟梁燕娟尤永森
赖玉萍++张舟++梁燕娟++尤永森


[摘要]目的 探讨慢性肾脏病(CKD)患者活性维生素D3、微炎症、颈动脉粥样硬化之间的关系,活性维生素D3是否可以改善颈动脉粥样硬化及可能的机制。方法 选择2014年7月~2015年7月在我院确诊为CKD的非透析患者96例,按肾小球滤过率(GFR)分为三组,A组为CKD3期,B组为CKD4期,C组为CKD5期,每组32例,每组予骨化三醇0.25 μg/d,疗程1年。三组治疗前后测定25羟维生素D3[25(OH)2D3]、超敏C反应蛋白(hs-CRP)、颈动脉中内膜厚度(IMT)。结果 三组治疗前25(OH)2D3下降、hs-CRP升高、IMT值下降,与CKD的进展相关,骨化三醇干预治疗后,hs-CRP、IMT值下降(P<0.05),hs-CRP、IMT值下降程度与25(OH)2D3上升成正相关(P<0.05)。结论 25(OH)2D3水平、微炎症状态是CKD患者的颈动脉粥样硬化的相关性因素,骨化三醇可通过改善患者的微炎症状态,进而改善颈动脉粥样硬化。
[关键词]慢性肾脏病;活性维生素D3;颈动脉粥样硬化;颈动脉中内膜厚度;微炎症
[中图分类号] R692 [文献标识码] A [文章编号] 1674-4721(2017)06(b)-0045-03
[Abstract]Objective To investigate the relationship between active vitamin D3,micro-inflammation and carotid atherosclerosis in patients with chronic kidney disease(CKD),and whether active vitamin D3 could improve carotid atherosclerosis and the possible mechanism.Methods 96 non-dialysis patients diagnosed as CKD in our hospital from July 2014 to July 2015 were divided into three groups according to the glomerular filtration rate (GFR),group A was CKD3 stage,group B was CKD4 stage,group C was CKD5 stage,and each group had 32 cases.Each group was given Calcitriol of 0.25 μg/d for 1 year.25 hydroxyvitamin D3 [25 (OH)2D3],hypersensitivity C reactive protein (hs-CRP) and carotid intima-media thickness (IMT) before and after treatment in the three groups were measured.Results 25 (OH)2D3 was decreased,hs-CRP increased and IMT decreased before treatment in the three groups which was associated with the progress of CKD,then after Calcitriol treatment,hs-CRP and IMT decreased (P<0.05).The decrease degree of hs-CRP and IMT was positively correlated with the increase of 25 (OH)2D3 (P<0.05).Conclusion 5 (OH)2D3 level and micro-inflammatory status are the factors of carotid atherosclerosis in patients with CKD,Calcitriol can improve carotid atherosclerosis by improving the Micro inflammation.
[Key words]Chronic kidney disease;Active vitamin D3;Carotid atherosclerosis;Carotid intima-media thickness;Micro-inflammation
慢性腎脏病(CKD)发病率高,最常见的并发症和首要死亡原因是心脑血管疾病。动脉壁内粥样斑块是预测心脑血管疾病的指标,炎症是动脉壁内粥样斑块形成的关键病理机制[1],是慢性肾衰竭患者心血管事件的独立危险因素之一。慢性肾脏病Ⅲ~Ⅳ期的患者普遍存在活性维生素D3缺乏及微炎症状态[2]。维生素D在维持心血管系统稳定方面发挥重要作用,还具有抗炎作用[3]。本研究旨在探讨慢性肾脏病不同分期中活性维生素D3、微炎症、颈动脉粥样硬化之间的关系,并予维生素D3干预,观察活性维生素D3是否可以改善颈动脉粥样硬化以及可能的机制,为临床心血管疾病的有效干预开辟新的途径,提高慢性肾脏病患者的生存率。
1资料与方法
1.1一般资料
选择2014年7月~2015年7月在我院肾内科确诊为慢性肾脏病的非透析患者,共96例,依据2002年美国NKF-K/DOQ I肾功能分期标准,按简化MDRD公式计算GFR,将患者分为三组,每组32例。……
